How do you approach monitoring when using combination JAK inhibitors and methotrexate in RA?

It is important to return to the package insert and/or the original clinical trials for these medications when considering options for care and use. Tofacitinib, for example, when tested for the management of rheumatoid arthritis, was in phase 2 and 3 studies in combination with DMARDs, including methotrexate, but excluding azathioprine and cyclosporine. Therefore we have safety and efficacy data on the combination of this JAKi and methotrexate and can vouch for the combination. Baricitinib was tested alone or in combination with methotrexate, so we have safety and efficacy data [Fleishmann et al., PMID 27723271]. The package insert for upacitinib outlines the effect of monotherapy only, but upacitinib + MTX has been evaluated in the SELECT...